Adjuvant Ribociclib May Be ‘Promising’ in HR+/HER2– Breast Cancer

Commentary
Video

Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.

“Reassuring” findings may support the use of ribociclib (Kisqali) as a treatment escalation option in the adjuvant setting for patients with hormone receptor (HR)–positive, HER2-negative breast cancer, said Neil M. Iyengar, MD, in a discussion with CancerNetwork® at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Iyengar, a breast oncologist in in the Department of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine in New York City, New York, as well as the co–editor-in-chief of the journal ONCOLOGY®, stated that ribociclib appeared to be well tolerated among the aforementioned patient population based on updated results from the phase 3 NATALEE trial (NCT03701334).

Longer-term follow-up data from the trial highlighted that no adverse effects (AEs) of special interest or clinically relevant AEs increased by more than 1% since the time of the initial analysis, and that the treatment discontinuation rate increased by 0.8%. Additionally, patients mostly discontinued treatment with ribociclib following liver-related AEs.

Transcript:

We’re getting a lot of data for the CDK4/6 inhibitors. We’ve now seen more updated data from NATALEE for adjuvant ribociclib, and what’s reassuring about those data is we continue to see that the toxicity profile is pretty good. It’s well tolerated, and this is particularly important because ribociclib is dosed differently in the adjuvant setting than in the metastatic setting. These longer-term follow-up data are important from a toxicity perspective. We are continuing to await longer-term follow-up from NATALEE, but the initial data and the follow-up data here at [SABCS] are looking very promising for the use of ribociclib in the adjuvant setting.

What’s also unique about NATALEE is the inclusion of patients with higher-risk but node-negative breast cancer. This is a population for which we don’t have an approval yet for CDK4/6 inhibitors, and it could potentially give us an option for escalating therapy in this patient population.

Reference

Hortobagyi G, Stroyakovsky D, Yardley D, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX; abstract GS03-03.

Recent Videos
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Related Content